Pfizer has acquired 50% stake in IGNITE Immunotherapy, an oncolytic virus vaccine design, discovery, and development company.

Pfizer will have two seats on IGNITE’s board of directors and collaborate on the latter’s research programme for discovery of potential novel vaccinia viruses, as part of the transaction.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Furthermore, Pfizer will fund the research and development for three years and have an option to acquire IGNITE upon completion of the initial research programme.

"Pfizer aims to strengthen its position in next-generation immuno-oncology field through the acquisition."

Pfizer aims to strengthen its position in next-generation immuno-oncology field through the acquisition.

Both companies involved are based in the US.

South Korean financial services provider KDB Capital has acquired 6.7% stake in Anygen by purchasing 333,334 shares in the latter.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The target company is also based in South Korea and engaged in peptide synthesis.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now